GlassScriptPhysician profile
David L Klein
NPI 1790962942
$879.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $184.52 | 2019-2020 | |
| Lundbeck LLC | $152.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $126.10 | 2019 | |
| Shire North American Group INC | $111.24 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $71.72 | 2019 | |
| Neos Therapeutics, LP | $56.85 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $36.26 | 2019 | |
| Allergan, INC. | $32.29 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $26.91 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.06 | 2019 | |
| Neurocrine Biosciences, INC. | $21.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.77 | 2019 | |
| Adlon Therapeutics L.P. | $16.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.